6-Thioguanine for Crohn's disease during pregnancy: Thiopurine metabolite measurements in both mother and child

被引:20
作者
De Boer, NKH
Van Elburg, RM
Wilhelm, AJ
Remmink, AJ
Van Vugt, JMG
Mulder, CJJ
Van Bodegraven, AA
机构
[1] Vrije Univ Amsterdam Med Ctr, Dept Gastroenterol & Hepatol, NL-1007 MB Amsterdam, Netherlands
[2] Vrije Univ Amsterdam Med Ctr, Dept Paediat, Amsterdam, Netherlands
[3] Vrije Univ Amsterdam Med Ctr, Dept Pharm, Amsterdam, Netherlands
[4] Rode Kruis Hosp, Dept Obstet & Gynaecol, Beverwijk, Netherlands
[5] Vrije Univ Amsterdam Med Ctr, Dept Obstet & Gynaecol, Amsterdam, Netherlands
关键词
Crohn's disease; placental drug transfer; pregnancy; 6-thioguanine; 6-thioguaninenucleotides; teratogenicity;
D O I
10.1080/00365520510024089
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
6-Thioguanine is used as an escape thiopurine for treating inflammatory bowel disease patients intolerant or refractory to azathioprine, 6-mercaptopurine or methotrexate. Case reports show conflicting data on the use of 6-thioguanine throughout pregnancy. The administration of the standard thiopurines is believed to be relatively safe. We describe two patients with Crohn's disease treated with low-dose 6-thioguanine during all trimesters of their pregnancies. The pregnancies resulted in two healthy infants: without congenital abnormalities, laboratory signs of myelosuppression or hepatocellular injury. Thiopurine metabolites were measured in mother and infant. Significantly lower levels of 6-thioguaninenucleotides were found in the erythrocytes of the infant compared to the mother ( ratio 1: 12). Further studies are needed to determine the clinical importance of thiopurine metabolite measurements during pregnancy in mother and child.
引用
收藏
页码:1374 / 1377
页数:4
相关论文
共 17 条
[1]   Thiopurines in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring and clinical recommendations [J].
Al Hadithy, AFY ;
de Boer, NKH ;
Derijks, LJJ ;
Escher, JC ;
Mulder, CJJ ;
Brouwers, JRBJ .
DIGESTIVE AND LIVER DISEASE, 2005, 37 (04) :282-297
[2]  
ARTLICH A, 1994, EUR J PEDIATR, V153, P488, DOI 10.1007/BF01957002
[3]  
de Jong D, 2001, GUT, V49, P874
[4]   Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease - Implications for therapy [J].
Derijks, LJJ ;
Gilissen, LPL ;
Engels, LGJB ;
Bos, LP ;
Bus, PJ ;
Lohman, JJHM ;
Curvers, WL ;
van Deventer, SJH ;
Hommes, DW ;
Hooymans, PM .
THERAPEUTIC DRUG MONITORING, 2004, 26 (03) :311-318
[5]   6-Thioguanine seems promising in azathioprine- or 6-mercaptopurine-intolerant inflammatory bowel disease patients: a short-term safety assessment [J].
Derijks, LJJ ;
de Jong, DJ ;
Gilissen, LPL ;
Engels, LGJB ;
Hooymans, PM ;
Jansen, JBMJ ;
Mulder, CJJ .
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2003, 15 (01) :63-67
[6]   6-thioguanine can cause serious liver injury in inflammatory bowel disease patients [J].
Dubinsky, MC ;
Vasiliauskas, EA ;
Singh, H ;
Abreu, MT ;
Papadakis, KA ;
Tran, T ;
Martin, P ;
Vierling, JM ;
Geller, SA ;
Targan, SR ;
Poordad, FF .
GASTROENTEROLOGY, 2003, 125 (02) :298-303
[7]   Thioguanine: A potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine [J].
Dubinsky, MC ;
Feldman, EJ ;
Abreu, MT ;
Targan, SR ;
Vasiliauskas, EA .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2003, 98 (05) :1058-1063
[8]   6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease [J].
Dubinsky, MC ;
Yang, HY ;
Hassard, PV ;
Seidman, EG ;
Kam, LY ;
Abreu, MT ;
Targan, SR ;
Vasiliauskas, EA .
GASTROENTEROLOGY, 2002, 122 (04) :904-915
[9]  
Ferrero Simone, 2004, Archives of Gynecology and Obstetrics, V270, P79
[10]   The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: A retrospective cohort study [J].
Francella, A ;
Dyan, A ;
Bodian, C ;
Rubin, P ;
Chapman, M ;
Present, DH .
GASTROENTEROLOGY, 2003, 124 (01) :9-17